Wei Yue, Ph.D.

---

Summary

My research program focuses on studying novel mechanisms involved in regulation of OATP1B1 and OATP1B3 transport function. The long-term goal of my laboratory is to establish a mechanistic model to predict OATP-mediated drug-drug interactions, toxicities and inter-individual variability in drug response. Multi-disciplinary approaches are utilized including: 1) Sandwich-cultured primary human hepatocytes model; 2) Physiologically based pharmacokinetic (PBPK) modeling approach to assess clinically relevant DDIs; 3) Pharmacogenomics studies of drug transport proteins; 4) Post-translational regulation of OATP transporters; 5) Confocal microscopy to study trafficking of the transport proteins.

Academic Awards

---

Publications & Presentations

21. Zheng W, Krasinskas A, Yue W, Wang H. OATP1B3 is a novel immunohistochemical marker to discriminate well differentiated hepatocellular carcinoma from its benign hepatocellular mimickers. Modern Pathology. In Press; 32 (S2) : 60

22. Alam K, Crowe A, Wang X, Zhang P, Ding K, Li L, Yue W. Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions. International Journal of Molecular Sciences. 2018; 19 : 855

23. Alam K, Farasyn T, Ding K, Yue W. Characterization of liver- and cancer-type-organic anion transporting polypeptide (OATP) 1B3 messenger RNA expression in normal and cancerous human tissues. Drug Metabolism Letters. 2018

24. Alam K, Farasyn T, Crowe A, Ding K, Yue W. Treatment with Proteasome Inhibitor Bortezomib Decreases Organic Anion Transporting Polypeptide (OATP) 1B3-Mediated Transport in a Substrate-Dependent Manner. Public Library of Science ONE. 2017; 12 : e0186924

25. Pahwa S, Alam K, Crowe A, Farasyn T, Sibylle N, Hatley O, Ding K, Yue W. Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport. Journal of Pharmaceutical Sciences. 2017; 106 : 2123

Grants

1. Regulation of organic cation transporter 1 transport function by lysine deacetylase 6: implications in drug-nutrient interactions. Non-federal. Start Date: 2025. End Date: 2026.

2. Equipment supplement award-Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitors . NIH. Start Date: 2024. End Date: 2026.

3. Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitors . NIH. Start Date: 2022. End Date: 2026.

4. Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitors . Misc Non-Federal. Start Date: 2022. End Date: 2022.

5. Lysine Acetylation: A novel mechanism governing organic anion transporting polypeptides OATP1B1- and OATP1B3-mediated transport. Misc Non-Federal. Start Date: 2021. End Date: 2022.

Awards and Honors

1. ASPET. ASPET Faculty Scholars. Date: 2025.


2. OUHSC. Regents’ Award for Superior Teaching. Date: 2024.


3. WiSDMH at OUHSC. Recognition of OUHSC Women in Science Dentistry Medicine and Health. Date: 2022.


4. OUHSC. Member of Educators for Excellence of OUHSC. Date: 2022.


5. OUHSC. Provost’s Teaching Award-Early Career Faculty . Date: 2021.

Education

1. Degree: Postdoctoral training. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Date: 2008.


2. Degree: Postdoctoral Training. Lineberger Comprehensive Cancer Center, Univeristy of North Carolina at Chapel Hill. Date: 2007.


3. Degree: Ph D. Peking Union Medical College and Shandong University, China. Date: 2001.


4. Degree: MS. Shandong University, China. Date: 1998.


5. Degree: BS. Shandong Agricultural University, China. Date: 1995.

Administrative Assignments

no results